Environmental, Neuro-immune, and Neuro-oxidative Stress Interactions in Chronic Fatigue Syndrome.
Bjørklund, Geir, Dadar, Maryam, Pivina, Lyudmila et al. · Molecular neurobiology · 2020 · DOI
Quick Summary
This review looked at how ME/CFS develops by examining immune system problems, oxidative stress (cellular damage from harmful molecules), infections, and nutritional issues. Researchers found that people with ME/CFS often have changes in their immune cells and proteins, along with signs of cellular damage that could explain fatigue, pain, and other symptoms. The study suggests that treatments targeting oxidative stress and nutrition might help, though more research is needed.
Why It Matters
This comprehensive review bridges multiple biological mechanisms implicated in ME/CFS, providing a unifying framework that may guide future diagnostic biomarker validation and targeted therapeutic development. For patients, understanding these interconnected pathways offers hope for personalized treatment approaches targeting immune dysfunction, oxidative stress, and nutritional repletion.
Observed Findings
Modifications in immunoglobulin contents and B/T cell phenotypes are frequently reported in ME/CFS patients
Natural killer cell cytotoxicity is consistently decreased in CFS populations
Activation markers and protein kinase R (PKR) activity show moderate diagnostic performance
Activated nitro-oxidative pathways are associated with key ME/CFS symptoms
Viral and bacterial infections, as well as nutritional deficiencies, correlate with worsening immune-oxidative dysfunction
Inferred Conclusions
Multiple interconnected biological pathways—immune dysregulation, oxidative stress, infection, and nutritional status—contribute to ME/CFS pathophysiology rather than a single causative mechanism
Some immune biomarkers (PKR activity, activation markers) have potential diagnostic utility and warrant external validation
Antioxidant and lipid replacement therapies may address underlying pathophysiology and merit further clinical investigation
Environmental stressors and infectious triggers exacerbate underlying immune-oxidative dysfunction
Remaining Questions
Which immune and oxidative biomarkers have sufficient sensitivity and specificity for clinical diagnostic use, and can they be standardized across laboratories?
What This Study Does Not Prove
This review does not establish causation—it describes correlations between biomarkers and symptoms. It does not validate any single biomarker as definitively diagnostic for ME/CFS, nor does it prove that antioxidant or lipid replacement treatments are effective in clinical practice. The findings represent associations observed in published studies of varying quality and cannot determine which factors are primary versus secondary.
Do infections trigger ME/CFS in genetically predisposed individuals, or do they exacerbate pre-existing dysfunction—and what is the timeline for immune recovery?
Which antioxidant or micronutrient interventions are most efficacious in specific ME/CFS subgroups, and what dosing and duration are optimal?
How do sex hormones, genetic polymorphisms, and the microbiome intersect with immune-oxidative pathways to explain disease heterogeneity?